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Abstract
AIM: To investigate the role of SCCA2 and other SCCA1
molecules in the process of hepatitis B virus (HBV) binding
to mammalian cells.
METHODS: SCCA1 and SCCA2 were isolated from HepG2.
Binding protein (BP) genes were obtained through PCR.
Recombinant baculoviruses expressing SCCA1, SCCA2,
BP, and different mutants were constructed and utilized
to infect mammalian cells to investigate the binding ability
of infected cells to HBV.
RESULTS: A SCCA1 gene (A1) was isolated from HepG2,
but it appeared to lack the binding ability of infected cells
to HBV. Two mutants, A1-BP and BP-A1, were constructed
by interchanging the carboxyl terminal of A1 and BP. Cells
expressing A1-BP showed an increased virus binding
capacity, but not BP-A1. Comparison of A1 sequence with
the sequence of BP indicated the presence of only three
amino acid changes in the carboxyl terminal, two of them
were found in the reactive site loop (RSL) of SCCA1.
Primary structure assay revealed that the hydrophobicity
of BP and AJ515706 in this domain was strong, but A1
was relatively weak. Changing the aa349 of A1 from low
hydrophobic glutamic acid to high hydrophobic valine enhanced
HBV binding. In contrast, HBV binding was reduced by
changing the aa349 of BP from valine to glutamic acid.
CONCLUSION: The results suggest that the hydrophobicity
of RSL of SCCA1 may play an important role in HBV
binding to cells.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Hepatitis B virus (HBV) is able to infect only humans or
higher primates and shows a strong tropism for liver
parenchymal cells. These characteristics and the lack of cell
lines that support productive HBV replication in vitro have
impeded the identification of HBV receptors. A number of
receptor candidates for HBV have been reported, including
receptors for immunoglobulin A (IgA), human interleukin-6
and annexin V. But these results are controversial, and no
conclusive and convincing biological data could be obtained
to fully demonstrate the functional role of these proteins in
HBV binding and internalization[1]. Studies using synthetic
preS1(21-47) peptides and corresponding antibodies to
prevent HBV attachment to HepG2 have identified the preS1
of the L protein as one of the important sites possibly involved
in HBV infection[2-4]. A recent candidate for HBV cellular
receptors is HBV-binding proteins (BP), isolated from the
plasma membranes of HepG2 by using a tetravalent derivative
of the preS1(21-47) sequence[5]. HepG2 cells after transfection
of BP cDNA showed an increased virus binding capacity,
while Chinese hamster ovary cells, which normally do not bind
to HBV, acquired susceptibility to HBV binding after
transfection. BPs encode for a protein of 390 amino acids.
Comparison of BP sequence with the sequence of SCCA1, a
member of serpin superfamily cloned by Suminami et al[6],
indicated the presence of only three amino acid changes (aa351,
aa357 and aa389). BP is also a member of SCCA1. The serpin
is a superfamily of structurally well-conserved protein presented
in plants, animals, fungi, viruses, and involved in regulating of
a variety of biological events[7]. When De Falcon et al[5], isolated
HBV-BP from HepG2, 12 independent recombinant clones
were sequenced, showing that the sequences corresponding to
SCCA1, SCCA2, and HBV-BP were equally represented.
SCCA2, another member of serpin, is found to be 91% close
to SCCA1. Recently, Moore et al[8], isolated another SCCA1
from HepG2, presenting four amino acid substitutions to BP,
and confirmed that transfection of this SCCA1 into mammalian
cells resulted in increased HBV binding. But the function of
SCCA2 is still not known. In order to understand the role of
SCCA2 and other SCCA1 in the process of HBV binding to
mammalian cells, recombinant baculoviruses expressing
SCCA1, SCCA2, BP, and different mutants were constructed
and the binding ability of infected cells to HBV was
investigated using infected mammalian cells.
MATERIALS AND METHODS
Cloning and sequencing of SCCA1, SCCA2, and BP
Primers were synthesized according to the sequences of
BPs (Table 1) by Shanghai Boya Company. Total RNA was
purified from HepG2 cells using TRIzol (Invitrogen). Reverse
transcription was primed using BP2. cDNA was used in a
nested PCR reaction to amplified target genes (the external
pair of primers were BP1 and BP2, and the internal pair
of primers were BP3 and BP4). Cycling for both reactions
was performed as follows: at 94 ℃ for 50 s, 25 cycles at 94 ℃
for 50 s, at 50-58 ℃ for 50 s, at 72 ℃ for 1 min, followed
by 1 cycle at 72 ℃ for 10 min. Products of the same length
to the target genes were amplified when annealing temperature
ranged between 50 ℃ and 58 ℃. PCR-amplified products
under different annealing temperatures were recovered
respectively using a gel extract kit (Shanghai Huashun Company)
and used directly in ligation with pMD18-T (Dalian Takara
Company). Sequencing was performed by Shanghai Boya
Company. Sequences were compared with published sequences
in GenBankTM, and submitted to GenBankTM. The product
at 56 ℃ was one SCCA1 (named A1, accession number
AY245781). The product at 52 ℃ was one SCCA2 (named
A2, accession number AY245782). Comparison of  A1 sequence
with BP sequence indicated only five amino acid changes
(aa185, aa202, aa349, aa351, aa389). Then A1 was mutated
through PCR to obtain the same BP[5] reported. Inserted
genes were confirmed by sequencing.
Table 1  Sequences of primers
Primer Sequence
BP1 5’- CAC AGG AGT TCC AGA TCA CAT CGA G -3’
BP2 5’- CTG GAA GAA AAA GTA CAT TTA TAT GTG GGC -3’
BP3 5’- CCG CTA GCT CAC CAT GAA TTC ACT CAG -3’
BP4 5’- CCG TCG ACT CTA CGG GGA TGA GAA TCT -3’
BPf 5’- GGA TCC ATG AAT TCA CTC AGT G -3’
BPr 5’- CTC GAG CTA CGG GGG TGA GAA TC -3’
EGf1 5’- GAT ATC ATG GTG AGC AAG GGC G -3’
EGf2 5’- GTC GAC TTA CTT GTA CAG CTC GTC C -3’
Construction of recombinant donor plasmids: pFB-A1, pFB-
A2, pFB-BP, and pFB-EGFP
A1, A2, and BP were used as templates for a pair of primers
(BPf  and BPr, Table 1). The amplified products were inserted
into the donor plasmid pFastBacl (Invitrogen) to construct pFB-
A1 and pFB-A2 and pFB-BP (Figure 1). EGFP gene was
amplified from pEGFP (Clontech) using primers Egf1 and
Egf2. The obtained fragments were cloned into pFastBacDual
(Invitrogen) to generate pFBD-EGFP (Figure 1). The sequences
of  the inserts were confirmed by sequencing.
Generation of recombinant baculoviruses[9]
Recombinant donor plasmids were transformed into DH10Bac
competent cells (Invitrogen). Then the transformed cells
were plated on LB plates containing X-gal (Sigma), IPTG
(Sigma), gentamycin, kanamycin, and tetracycline for selection
of white colonies. The white colonies were cultured in liquid
LB containing the same three antibiotics, and the transposed
bacmids were extracted by alkaline lysis. There were compl-
ementary sequences of M13 primer flanking the LacZ gene
of bacmids. The length of PCR-amplified products using
M13 primer was used to confirm the transposition. Cycling
for both reactions was performed as follows: at 94 ℃ for
50 s, 30 cycles at 94 ℃ for 50 s, at 55 ℃ for 50 s, at 72 ℃
for 3 min, followed by 1 cycle at 72 ℃ for 10 min.
Figure 1  Map of pFB-targets (target is A1, A2 or BP respectively) and pFBD-
EGFP.
The resultant bacmids were then used to transfect Sf9
(Invitrogen) cells by using liposome reagent (Cellfectin,
Invitrogen) to produce recombinant baculoviruses BacA1,
BacA2, BacBP, and BacEGFP. Supernatant of cell culture
containing recombinant baculoviruses was collected after 4 d
and used to reinfect Sf9 cells to obtain baculoviruses with a
higher titer.
Harvest and plaque assay of baculoviruses
Sf9 cells about 80% confluence were seeded in a six-well
plate, and incubated at 28 ℃ for 1 d. Baculoviruses were
added to each well of six-well plates at serial dilution and 2 mL
0.8% low-melting agarose (Sigma) prepared using Grace’s
medium (Invitrogen) was overlaid after 1 h. The plate was
stored at 28 ℃ for 5 d, and the plaques stained with 1%
neutral red were counted.
Gene transfer to mammalian cells using recombinant
baculoviruses
About 5×104 mammalian cells were seeded in each well of
a 24-well plate. The medium was removed after 12 h at 37 ℃,
and 500 µL Sf9 culture supernatant containing recombinant
baculoviruses was added. New medium was used after 8 h
at 37 ℃ and cultured for 48 h.
HBV binding assay and HBV DNA harvest
About 5×104 mammalian cells were seeded in each well of
a 24-well plate. The medium was removed after 16 h at 37 ℃,
and washed once with D-hanks. To each well, 200 µL Dane’s
particles (2×107/well, Beijing Institute of Biological Products)
was added and diluted with an appropriate growth medium
of mammalian cells and the cells were incubated at 37 ℃
in a CO2 incubator for 4 h. The entire medium was aspirated
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Table 2  Comparison of the relative binding to HBV in different cell
lines
Cell line                      Source       HBV DNA (copies/sample)
HepG2       Human/hepatocellular 263 382±16 302
                 carcinoma
WI-38       Human/lung fibroblast 186 215±15 236
BNL 1ME A.7R.1                  Mice/liver 169 221±13 489
 CHO                 Mice/ovary 105 400±25 076
off and washed twice with PBS and the cells were
collected into an Eppendorf  tube. Total HBV DNA was
harvested using protease K after separation of  cell nuclei
and plasma.
Fluorescence PCR analysis
HBV DNA was analyzed using a HBV fluorescence PCR
diagnostic kit (Xiamen Xingchuang Company). Cycling was
performed in a Roton-gene real-time 2000 PCR system as
follows: at 94 ℃ for 180 s, 50 cycles at 94 ℃ for 1 s, at 53 ℃
for 20 s. The data were analyzed and exported by fluorescence
PCR analysis software.
Hydrophobicity of primary structure of target genes
Kyte–Doolittle method included in protean program of
DNASTAR software was used to analyze hydrophobicity.
The average length of amino acid residues used was by default,
nine residues. The horizontal line represented the site of amino
acids, and the vertical line represented the hydrophobicity
index. Positive index meant amino acids were hydrophobic,
and negative meant hydrophilic. The larger the absolute
value, the stronger the hydrophobicity.
RESULTS
HBV binding to HepG2 cells and WI-38 cells
The following cell lines were used to study the binding to
HBV: HepG2, WI-38, BNL 1ME A.7R.1, and CHO. Cells
were incubated with an appropriate medium containing Dane’s
particles. Cell-associated HBV DNA was harvested after being
washed with PBS and quantified using real-time fluorescence
PCR (Table 2). HepG2 cells could bind to HBV in some
degree, and some non-specific bindings to viruses were found
in other non-tropistic cell lines. WI-38 cells were observed
to have a comparatively higher efficiency of report gene
transfer and expression[10]. So WI-38 cells were selected as target
cells in following research.
HBV infection to WI-38 cells expressed different target proteins
Recombinant baculoviruses (BacA1, BacA2, BacBP, and
BacEGFP) infected WI-38 cells, respectively. Dane’s particles
were added to the cells after 48 h. HBV DNA was extracted
after 4 h and quantified (Figure 2). We observed no increase
in cell-associated virus DNA in cells infected with BacA1
and BacA2, a significant increase in cells infected with BacBP
(P<0.05) compared with mock infected cells (infected with
BacEGFP) and uninfected cells (blank control), suggesting
that expression of BP could make WI-38 acquire susceptibility
to HBV binding, but not A1 and A2.
Figure 2  HBV binding to WI-38 cells infected with dif ferent recombinant
balculoviruses; blank: uninfected cells; mock: BacEGFP infected cells.
SCCA1 protein sequence comparison
The expression of A1 could not enhance HBV binding to
cells. Moore et al[8], reported that they isolated a SCCA1
gene (GenBankTM accession number AJ515706) from
HepG2 cells by PCR and transfection of this SCCA1 into
mammalian cells (both hepatocyte-derived and of non-
hepatocyte origin) resulted in increased HBV binding. Site-
directed mutagenesis in RSL was utilized to create two
AJ515706 gene mutants, P3 and P14. There was no
significant difference in binding between the wild type
SCCA1 and either RSL mutant. Thus, except A1, the other
four SCCA1 protein (BP, AJ515706, P3, P14) expression
could increase cell binding to HBV. Based on the sequence
comparison (Table 3), amino acid changes of  A1 at aa185,
aa202, aa349 and aa351 were specific.
Construction of chimeric mutants of BP and A1 and their binding
to HBV
The function of serpin involved exposure of the reactive
site loop (RSL) to the active site of proteinases[7]. In order
to understand the amino acid changes involved in HBV
binding ability, two chimeric mutants, BP-A1 and A1-BP,
were constructed by interchanging the fragments of BP and
A1 after aa342 (Figure 3).
Then, recombinant baculoviruses containing BP-A1 and
A1-BP were generated and infected WI-38 cells were used
Table 3  Amino acid sequence differences among five SCCA1 proteins
Amino acid residue 16                      47                     105                   185                    202                    341                   349                     351                   352                   389
BP  F                        D                        N                       Q                        P                        A                        V                         A                        F                        P
AJ515706  S                        N                        T                        Q                        P                        A                        V                        A                         F                        S
P3  S                        N                        T                        Q                        P                        A                        V                        A                        A                        S
P14  S                        N                        T                        Q                        P                        R                        V                        A                         F                         S
A1  F                        D                        N                       R                         S                        A                        E                        G                         F                         S
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to investigate their functions in HBV binding (Figure 4). It
showed that cells expressing A1-BP could bind to HBV,
but BP-A1 could not. Apparently, the susceptibility of SCCA1
to HBV was significantly affected by amino acid changes
after aa342.
Figure 3  Construction of chimeric mutants of BP and A1.
Figure 4  HBV binding to WI-38 cells expressing chimeric mutants of BP and
A1. Blank: uninfected cells; mock: BacEGFP infected cells.
Hydrophobicity/hydrophilicity analysis of primary structure of
several SCCA1 protein
Comparison of hydrophobicity/hydrophilicity of five SCCA1
proteins (BP, AJ515706, P3, P14, and A1) found that the four
proteins with HBV binding ability displayed a relatively high
hydrophobicity, and the peak value of hydrophobicity of
these proteins was above 2.0. But the peak value of A1, the
protein without HBV binding ability, was just 1.07 (Figure 5).
aa349 site-directed mutagenesis of BP and A1 affected HBV
binding ability
A1 differed from all the other four proteins for the presence
of two residue mutations, V349E and A351G between aa344
and aa354. Notably, at aa349 of A1, it was a low hydrophobic
glutamine residue, but not a high hydrophobic valine residue.
It was assumed that the hydrophobicity between aa344 and
aa354 might have played a role in the process of SCCA1 binding
to HBV. To elucidate this hypothesis, we constructed BPV349E
and A1E349V utilizing the site-directed mutagenesis method
at the aa349 of BP and A1, and found that a deletion mutant
BPN342 deleted the fragments after BP aa342 (Figure 6).
The hydrophobicity of BPV349E between aa344 and aa354
was markedly reduced, but A1E349V was reverse (Figure 5).
Recombinant baculoviruses of these mutants were constructed
and infected WI-38 cells were used to analyze the binding
of cells to HBV. The results revealed that the expression
of A1E349V could enhance cell binding to HBV, but BPV349E
could not, suggesting that aa349 was of  pivotal importance
to the function of SCCA1 (Figure 7). Surprisingly, in the case
of BPN342 expression, some virus-cell binding ability still
remained, implying that the binding of BP to HBV might
involve several sites, or aa344-aa354 region was not directly
involved in the binding. But the altered hydrophobicity of
this region might indirectly lead to conformational changes
of HBV binding sites.
Figure 5  Hydrophobicity analysis of several SCCA1 proteins.
Figure 6  Construction of different SCCA1 mutants.
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DISCUSSION
BP and AJ515706 are two SCCA1 genes isolated from
HepG2 by De Falco et al[5], and Moore et al[8]. Mammalian
cells expressing both genes showed an increased HBV
binding capacity. But in this study, A1 isolated from HepG2
did not show the same capacity. A2, a SCCA2, which was
found to be 91% homologous to SCCA1, also lacked this
capacity.
BP, AJ515706 and A1 are of  a high sequence homology,
but they only have 4-7 different amino acids (Table 3). In
order to understand which amino changes were related to
HBV binding capacity, two mosaics, BP-A1 and A1-BP,
were constructed by interchanging the fragments of BP and
A1 at downstream aa342. The results showed that cells
expressing A1-BP could bind to HBV, but BP-A1 could not.
It seems that the changes of three amino acids between A1
and BP after aa342 were important in the binding to HBV.
Two of  the amino acid changes (aa349 and aa351) reside
in RSL. The hydrophobicity of A1 in RSL was relatively mild,
but that of  BP and AJ515706 was strong. We created two
mutants, A1E349V and BPV349E, by site-directed mutagenesis
at the aa349 of BP and A1. The mild hydrophobic glutamic
acid of A1 was changed into high hydrophobic valine.
Correspondingly, valine of BP was changed into glutamic
acid. Cells expressing A1E349V acquired HBV binding ability,
but BPV349E lost it. The results revealed that there was an
important correlation between hydrophobicity of SCCA1 RSL
and HBV binding capacity. The decreased hydrophobicity in
this region would lead to the reduction in levels of bound viruses.
In the hydrophobic conformation, DHBV particles were
able to bind to liposome and intact cells[11]. The strong
hydrophobicity of BP and AJ515706 in RSL might help
them to form stable complexes with HBV or some components
of cells, increase attachment to and entry in cells.
Serpin is a conformation-dependent protein. The relatio-
nship between structure and function is very special. Until
now, this has not been fully understood. The RSL of serpin
not only plays an important role in the inhibitory activity of
serpin, but also affects the whole conformation of  serpin.
The binding to ligands and the reciprocity between proteins
can occur at any site of  serpin. The conformational changes
on RSL may influence other regions of serpin interacting
with HBV. So, the RSL and its hydrophobicity are important
in the process of cell binding to HBV, but other regions on
BP may also interact with HBV. In this study, the result of
BPN342 might favor this explanation. Expression of BPN342
and deletion mutants of RSL, did not result in abrogation
of  enhanced virus binding to infected WI-38, suggesting
the complicated effect of serpin structure.
HepG2 is a cell line from hepatocellular carcinoma. The
surface components of each cell are not totally identical.
Some different SCCA1 genes were isolated from HepG2 using
the similar methods by De Falco et al[5], and Moore et al[8].
These SCCA1 genes have a high sequence homology, but their
functions in HBV binding differ markedly. In the normal
hepatocytes, are there different SCCA1 genes that express
simultaneously? Does the expression of different SCCA1
have a relationship with the susceptivity of cells to HBV
and the cytopathological changes after HBV infection? Further
research on these problems may contribute to understanding
the mechanism of interaction between hepatocytes and HBV.
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Figure 7  HBV binding to WI-38 cells expressing site-mutants of BP and A1.
Blank: uninfected cells; mock: BacEGFP infected cells.
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